TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial (Q43472706)

23 November 2017

title

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial (English)

1 reference

23 November 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

1

Takayuki Yoshino

1 reference

23 November 2017

16

Atsushi Ohtsu

1 reference

23 November 2017

13

Taito Esaki

1 reference

23 November 2017

12

Toshikazu Moriwaki

1 reference

23 November 2017

4

Tomohiro Nishina

1 reference

23 November 2017

3

Kentaro Yamazaki

1 reference

23 November 2017

8

Kensei Yamaguchi

1 reference

23 November 2017

9

Kei Muro

1 reference

23 November 2017

7

Akihito Tsuji

1 reference

23 November 2017

2

Nobuyuki Mizunuma

1 reference

23 November 2017

10

Naotoshi Sugimoto

1 reference

23 November 2017

11

Yasushi Tsuji

1 reference

23 November 2017

14

Chikuma Hamada

1 reference

23 November 2017

15

Takanori Tanase

1 reference

23 November 2017

Yoshito Komatsu

5

1 reference

23 November 2017

Hideo Baba

series ordinal

6

1 reference

23 November 2017

publication date

28 August 2012

1 reference

Lancet Oncology Commission

23 November 2017

published in

1 reference

23 November 2017

volume

13

1 reference

23 November 2017

issue

10

1 reference

23 November 2017

page(s)

993-1001

1 reference

23 November 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

EGFR inhibitors embrace KRAS

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970345-5

7 January 2021

10.1016/S1470-2045(12)70345-5

Identifiers

DOI

1 reference

23 November 2017

1 reference